In Week of Mar 28, 2026, Gland Pharma Ltd (Pharma - API & CRAMS) is outperforming Nifty 500 with +15.9% relative strength. Fundamentals: Average.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 (ended December 31, 2025) earnings • Updated Feb 28, 2026
What: 100M unit capacity expansion driving 28-30% margin revenue
Impact: +₹325 Cr revenue
“Management stated: 'expanding cartridge fill and finish capacity from 40 million to 140 million units with investments of approximately INR 2,000 crore over the next five years'”
What: Sustained positive EBITDA from European CDMO business
Impact: +₹550 Cr revenue
“Management confirmed: 'Cenexi delivered an EBITDA of 1.4 million euros in Q3 FY26 in line with our guidance'”
What: 10 new US product launches driving immediate revenue
Impact: +₹225 Cr revenue
“Management reported: 'launched ten new products in the U.S.' with nine ANDAs filed”
Earnings deceleration risks from management commentary
Trigger: Delays beyond 2 quarters
Impact: -250 bps margin impact
Management view: Confident in maintaining 12-13% growth with upside if pending approvals come through
Monitor: Number of ANDA approvals per quarter
Trigger: EBITDA turns negative
Impact: -400 bps margin impact
Management view: Cenexi met quarterly sales target of EUR 50 million with positive EBITDA
Monitor: Cenexi quarterly EBITDA
Key quotes from recent conference calls
“We are expanding cartridge fill and finish capacity from 40 million to 140 million units with investments of approximately INR 2,000 crore over the next five years primarily towards BFS and ophthalmic lines, as well as CDMO contracts. — Arun Kumar”
“Adjusted EBITDA margins were 26% and adjusted PAT margins 16%. Growth was broad-based with strong results in both plants core business and Cenexi where we met our near-term quarterly sales target of euro 50 million. — Arun Kumar”
“In Q3 FY26, consolidated revenue was INR 16,954 million up 22% year-on-year. Consolidated adjusted EBITDA increased by 25% to INR 4,490 million. — Management”
“Given this momentum we are confident we can maintain full year FY26 growth... targeting 15% CAGR over the next 5 years. — Arun Kumar”
Forward-looking targets from management for FY26-FY30
Revenue Growth Target
12.5%
Implied PAT Growth
15%
OPM Guidance
26.5%
Capex Plan
₹2000 Cr
Key Milestones
• Cartridge capacity to 100M units by Q4 FY26
• Cenexi revenue to EUR 60M quarterly
• 15% CAGR target over 5 years
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +23% | +8% | Inflection Up |
| PAT (Net Profit) | +27% | -17% | Inflection Up |
| OPM | 26.0% | 0 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 28, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Gland Pharma Ltd's latest quarterly results (Dec 2025) show
Gland Pharma Ltd's profit is growing with an turning around (inflection up) trend.
Gland Pharma Ltd's revenue growth trend is turning around (inflection up).
Gland Pharma Ltd's operating margin is volatile.
Gland Pharma Ltd's long-term compounding rates
Gland Pharma Ltd's earnings growth is turning around (inflection up) with mixed signals on a sequential basis.
Gland Pharma Ltd's trailing twelve month (TTM) performance
Gland Pharma Ltd appears significantly overvalued based on our fair value analysis.
Gland Pharma Ltd's current PE ratio is 32.9x.
Gland Pharma Ltd's current PE is 32.9x.
Gland Pharma Ltd's price-to-book ratio is 3.0x.
Gland Pharma Ltd is rated Average with a fundamental score of 56.12/100. This score is calculated from objective financial metrics
Gland Pharma Ltd has a debt-to-equity ratio of N/A.
Gland Pharma Ltd's return ratios over recent years
Gland Pharma Ltd's operating cash flow is positive (FY2025).
Gland Pharma Ltd's current dividend yield is 1.04%.
Gland Pharma Ltd's shareholding pattern (Dec 2025)
Gland Pharma Ltd's promoter holding has remained stable recently.
Gland Pharma Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Gland Pharma Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Gland Pharma Ltd has 3 key growth catalysts identified from recent earnings analysis
Gland Pharma Ltd has 2 key risks worth monitoring
In Q3 FY26 (ended December 31, 2025), Gland Pharma Ltd's management highlighted
Gland Pharma Ltd's management has provided the following forward guidance for FY26-FY30
Based on quantitative research signals, here is why Gland Pharma Ltd may be worth studying
Gland Pharma Ltd investment thesis summary:
Gland Pharma Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
